A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) With a Food Effect Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adult Participants
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs TBI 223 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 10 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 May 2020.
- 10 Oct 2019 Planned primary completion date changed from 30 Aug 2019 to 15 Nov 2019.
- 10 Oct 2019 Status changed from active, no longer recruiting to recruiting.